Systemic Neoadjuvant and adjuvant Control by Precision medicine in rectal cancer (SYNCOPE) – approach on high-risk group to reduce metastases
Key facts
- Where
- Helsinki és Tampere, FinnországSee the 2 sites
- Phase
- 4. fázis
Where in Finnország
- HUS-YhtymaeHelsinki, FinnországTaking people
- Tampere University HospitalTampere, FinnországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- HUS-Yhtymae
- Trial code
- EU 2024-517149-15-00
- Record updated
- 2024. szeptember 24.
- Original description
Applying a systemic control with precision approach over the course of the rectal cancer therapy is logistically feasible Applying a systemic control and precision approach as a treatment strategy, recurrence-free survival of rectal cancer patients is improvedRead full original descriptionShow less
Applying a systemic control with precision approach over the course of the rectal cancer therapy is logistically feasible Applying a systemic control and precision approach as a treatment strategy, recurrence-free survival of rectal cancer patients is improved
Inclusion: rectal adenocarcinoma, 2) WHO performance status 0-1, assessed by the MDT to be able to undergo CAPOX (capecitabine and oxaliplatin) treatment, 3) mrEMVI+ and 4) assessed by the MDT to require either RT or CRT by the current standards. In general, indications for clinical rectal carcinoma MDT to recommend RT or CRT are: T3-4 tumor at mid- or low rectum location, involvement of lymph nodes, threatened operative margin or mrEMVI.
Exclusion: 1.) deficient MMR status, non-DPYD genotype 2) a contraindication to capecitabine, oxaliplatin or RT, 3) failing in blood tests that describe the adequate circulatory 4) liver and kidney function for chemotherapy.